Literature DB >> 32173111

Cost-Effectiveness of Preoperative OCT in Cataract Evaluation for Multifocal Intraocular Lens.

Ella H Leung1, Allister Gibbons2, Douglas D Koch3.   

Abstract

PURPOSE: To determine the cost effectiveness of an adjunctive screening OCT during the preoperative evaluation of a patient considering cataract surgery with a multifocal intraocular lens (IOL) implantation.
DESIGN: Cost-effectiveness analysis. PARTICIPANTS: A 67-year-old man with 20/60 vision undergoing evaluation for first-eye cataract surgery.
METHODS: The cost-effectiveness analysis of the reference patient undergoing a preoperative cataract examination with and without a screening OCT was performed, evaluating for vitreoretinal diseases including an epiretinal membrane, age-related macular degeneration, vitreomacular traction, and cystoid macular edema. It was assumed that patients with macular pathologies detected before surgery would receive a monofocal IOL and be referred to a retina specialist for evaluation and management. The Medicare reimbursable cost of an OCT was $41.81. All costs and benefits were adjusted for inflation to 2019 United States dollars and discounted 3% per annum over a 16-year time horizon. Probability sensitivity analyses and 1-way deterministic sensitivity analyses were performed to assess for uncertainty. MAIN OUTCOME MEASURES: Incremental cost-effectiveness ratio and incremental cost-utility ratio (ICUR) measured in quality-adjusted life years (QALYs).
RESULTS: Approximately 20.5% of patients undergoing cataract surgery may have macular pathologies, of which 11% may not be detected on the initial clinical examination. In the base case, an adjunctive preoperative OCT was cost effective from a third-party payer and societal perspective in the United States. In the probability sensitivity analyses, the ICURs were within the societal willingness-to-pay threshold of $50 000/QALY in approximately 64.4% of the clinical scenarios.
CONCLUSIONS: A preoperative screening OCT during the evaluation of a patient considering a multifocal IOL added to the costs of the cataract surgery, but the OCT increased the detection of macular pathologies and improved the QALYs over time. An adjunctive screening OCT can be cost effective from a third-party payer and societal perspective.
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32173111      PMCID: PMC7311225          DOI: 10.1016/j.ophtha.2020.01.049

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  38 in total

1.  SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.

Authors:  Melissa M Brown; Gary C Brown; Heidi B Lieske; Irwin Tran; Adam Turpcu; Shoshana Colman
Journal:  Retina       Date:  2016-02       Impact factor: 4.256

2.  Refractive outcomes after multifocal intraocular lens exchange.

Authors:  Eric J Kim; Ahmar Sajjad; Ildamaris Montes de Oca; Douglas D Koch; Li Wang; Mitchell P Weikert; Zaina N Al-Mohtaseb
Journal:  J Cataract Refract Surg       Date:  2017-06       Impact factor: 3.351

3.  Epiretinal membrane in diabetes mellitus patients screened by nonmydriatic fundus camera.

Authors:  Boris Knyazer; Orit Schachter; Ygal Plakht; Yonatan Serlin; Jenna Smolar; Nadav Belfair; Tova Lifshitz; Jaime Levy
Journal:  Can J Ophthalmol       Date:  2016-02       Impact factor: 1.882

4.  The epidemiology of vitreoretinal interface abnormalities as detected by spectral-domain optical coherence tomography: the beaver dam eye study.

Authors:  Stacy M Meuer; Chelsea E Myers; Barbara E K Klein; Maria K Swift; Yijun Huang; Sapna Gangaputra; Jeong W Pak; Ronald P Danis; Ronald Klein
Journal:  Ophthalmology       Date:  2014-12-31       Impact factor: 12.079

5.  Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.

Authors:  Ankoor R Shah; Lucian V Del Priore
Journal:  Ophthalmology       Date:  2009-07-09       Impact factor: 12.079

6.  Preoperative spectral-domain optical coherence tomography in patients having cataract surgery.

Authors:  Youssef Abdelmassih; Sylvain El-Khoury; Sophie Georges; Damien Guindolet; Eric Gabison; Isabelle Cochereau
Journal:  J Cataract Refract Surg       Date:  2018-05-08       Impact factor: 3.351

7.  Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T.

Authors:  Neil M Bressler; Wesley T Beaulieu; Maureen G Maguire; Adam R Glassman; Kevin J Blinder; Susan B Bressler; Victor H Gonzalez; Lee M Jampol; Michele Melia; Jennifer K Sun; John A Wells
Journal:  Am J Ophthalmol       Date:  2018-08-02       Impact factor: 5.258

8.  Macular disease detection with a swept-source optical coherence tomography-based biometry device in patients scheduled for cataract surgery.

Authors:  Nino Hirnschall; Christoph Leisser; Stephan Radda; Sophie Maedel; Oliver Findl
Journal:  J Cataract Refract Surg       Date:  2016-04       Impact factor: 3.351

9.  Dissatisfaction after multifocal intraocular lens implantation.

Authors:  Maria A Woodward; J Bradley Randleman; R Doyle Stulting
Journal:  J Cataract Refract Surg       Date:  2009-06       Impact factor: 3.351

10.  Incorporating Optical Coherence Tomography in the Cataract Preoperative Armamentarium: Additional Need or Additional Burden?

Authors:  Aditya Sudhalkar; Viraj Vasavada; Deepak Bhojwani; C V Gopal Raju; P Vasudev; Shraddha Jain; Mamidipudi R Praveen
Journal:  Am J Ophthalmol       Date:  2018-10-31       Impact factor: 5.258

View more
  2 in total

1.  Optical Coherence Tomography: Critical Tool to Manage Expectations after Cataract Extraction.

Authors:  Raquel Goldhardt; Bradley Simon Rosen
Journal:  Curr Ophthalmol Rep       Date:  2020-06-06

2.  Impact of lens opacity and axial length on concomitant screening of maculopathy by swept-source optical coherence tomography-based optical biometer.

Authors:  Yingyan Qin; Shaobi Ye; Liangping Liu; Mingxing Wu
Journal:  Ann Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.